Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, R&D spend, and cash-runway figures in Arcutis Biotherapeutics (ARQT) SEC documents can stretch across hundreds of pages. If you need to know how ZORYVE sales offset development costs or where the next PDE4 program stands, wading through every quarterly update is time-consuming and complex.
Stock Titan solves this problem with AI-powered summaries that turn raw disclosures into plain-English takeaways. Whether you are searching for “Arcutis quarterly earnings report 10-Q filing,” want “Arcutis insider trading Form 4 transactions,” or need an “Arcutis proxy statement executive compensation” breakdown, our engine surfaces the exact paragraph in seconds. Real-time alerts appear the moment an “Arcutis Form 4 insider transactions real-time” notice hits EDGAR, while cross-links let you compare each metric historically for quick “Arcutis earnings report filing analysis.”
Dive deeper without the jargon: jump straight to liquidity tables in the “Arcutis annual report 10-K simplified,” scan risk-factor changes, or review pivotal Phase 3 data inside an “Arcutis 8-K material events explained” filing. Many professionals rely on us for “understanding Arcutis SEC documents with AI” because our platform highlights option-exercise patterns under “Arcutis executive stock transactions Form 4,” flags non-recurring charges, and maps clinical timelines to projected market launches. With comprehensive coverage of every 10-K, 10-Q, 8-K, S-1, and Form 4, plus clear explanations, complex immuno-dermatology disclosures finally make sense.
UBS AG is offering Trigger Autocallable Contingent Yield Notes (unsubordinated, unsecured debt) linked to Regeneron Pharmaceuticals, Inc. common stock. The notes have an expected 30-month term, issuing 16 Jul 2025 and maturing 18 Jan 2028, with quarterly observation dates. Investors receive a fixed contingent coupon of 9.01 %–9.87 % p.a. ($0.2253–$0.2468 per $10 note) only if Regeneron’s closing price on an observation date is at least 60 % of its initial level (the “coupon barrier”).
Automatic call: The notes are redeemed early at par plus the quarterly coupon if Regeneron closes at or above its initial level on any observation date before final valuation. Early call may occur as soon as the first quarter, creating reinvestment risk.
Principal repayment: • If not called and the final level is ≥ the 60 % downside threshold, investors receive full principal.
• If the final level is < the downside threshold, repayment equals $10 × (1 + underlying return), resulting in a dollar-for-dollar loss beyond 40 % decline; maximum loss is 100 % of principal.
Key economics
- Issue price: $10; minimum purchase 100 notes ($1,000).
- Estimated initial value: $9.47–$9.72 (reflects underwriting discount, hedging and funding costs).
- Underwriting discount: $0.175 per note (1.75 %).
Risk highlights
- Market risk identical to holding Regeneron below the 60 % threshold at maturity.
- No participation in upside beyond fixed coupons; dividends on Regeneron are foregone.
- Credit risk of UBS: all payments depend on UBS AG’s ability to pay; notes are not insured.
- Liquidity risk: notes will not be listed; secondary market, if any, may be illiquid and priced below issue price.
- Conflicts of interest: UBS entities act as issuer, distributor, calculation agent and market maker.
- Tax treatment uncertain; UBS treats notes as prepaid derivatives with ordinary-income coupons.
Investor suitability: suitable only for investors who (1) can tolerate potential total loss, (2) believe Regeneron will remain above 60 % of its initial level, (3) are comfortable with UBS credit exposure, and (4) accept limited liquidity and capped return.
Arcutis Biotherapeutics, Inc. (ARQT) filed a Form 144 indicating a planned open-market sale of insider shares. The notice covers 5,750 common shares to be sold through Merrill Lynch on the NASDAQ around 07/14/2025. The broker-quoted aggregate market value is $86,654, implying an indicative price of roughly $15.07 per share. The filing shows 119,201,724 shares outstanding, so the proposed sale represents ~0.005% of the float.
The seller, Patrick Burnett (address: 3027 Townsgate Rd, Westlake Village, CA), acquired the shares on the same date via a stock-option exercise paid in cash. No relationship to the issuer is disclosed in the form. A review of the required three-month look-back reveals prior disposals by the same individual totaling 29,468 shares:
- 2,597 shares on 05/02/2025 for $39,442
- 3,871 shares on 05/08/2025 for $52,623
- 23,000 shares on 07/10/2025 for $346,047
Combining past and proposed transactions, Burnett intends to liquidate 35,218 shares for ~$524,766 in gross proceeds over the period. Form 144 asserts that the seller is not in possession of undisclosed material adverse information. No additional financial metrics, earnings data, or corporate developments are provided in the filing.
Arcutis Biotherapeutics, Inc. (ARQT) – Form 144 filing
An individual named Patrick Burnett has filed a Form 144 indicating an intention to sell up to 23,000 common shares of Arcutis Biotherapeutics. The proposed broker is Merrill Lynch (Columbus, OH), the targeted sale date is 10 July 2025, and the aggregate market value of the planned sale is $346,047. With 119,201,724 shares outstanding, the planned sale represents roughly 0.02 % of shares outstanding.
The filer previously sold shares during the past three months:
- 2,597 shares on 02 May 2025 for $39,442
- 3,871 shares on 08 May 2025 for $52,623
The shares being sold were acquired via a stock-option exercise on 10 July 2025, paid in cash. No additional financial or operational information about Arcutis is included in this short-form notice.
Arcutis Biotherapeutics (ARQT) filed a Form 4 disclosing that director Howard G. Welgus sold 9,208 common shares on 01 July 2025 at a weighted-average price of $13.8391 (price range: $13.65–$13.99). The sale was executed under a Rule 10b5-1 trading plan adopted on 11 March 2025 and scheduled to run through 29 May 2026.
Following the transaction, Welgus still beneficially owns 100,206 shares, held directly. No derivative security activity was reported. The filing was signed on 02 July 2025 by an attorney-in-fact.
This single transaction represents a modest reduction in the director’s holdings and does not, by itself, provide information on company fundamentals or near-term performance; however, investors often monitor insider sales for sentiment signals.
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) has submitted a Form 144 notifying the SEC of an intended sale of 9,208 common shares by insider Howard Welgus. The shares are to be brokered through Merrill Lynch on or about 01 July 2025 and carry an aggregate market value of roughly $127,431. With 119,201,724 shares outstanding, the contemplated transaction represents approximately 0.008 % of the float.
The stock being sold originates from three restricted-stock vesting events: 06 Jun 2023 (2,583 sh), 27 Feb 2024 (2,250 sh) and 31 May 2024 (4,375 sh). The filing also discloses previous dispositions by the same insider over the past three months—10,000 shares on 01 May 2025 for $146,357 and 10,139 shares on 18 Jun 2025 for $135,269—bringing total recent insider sales to 29,347 shares valued at $409,057.
No additional operational, earnings or strategic information is provided; the document solely fulfills Rule 144 notice obligations for this limited insider sale.
Director Howard G. Welgus of Arcutis Biotherapeutics (ARQT) reported a significant insider sale transaction executed on June 18, 2025. The director sold 10,139 shares of common stock at a weighted average price of $13.3715 per share, with individual transaction prices ranging from $13.2118 to $13.59.
Following the transaction, Welgus retains direct ownership of 109,414 shares of the company's common stock. The sale was conducted under a pre-established 10b5-1 trading plan initiated on March 11, 2025, which remains active until May 29, 2026.
Key transaction details:
- Transaction executed pursuant to Rule 10b5-1 trading plan
- Total transaction value approximately $135,575
- Represents a partial reduction of the director's holdings
- Transaction reported within required SEC filing deadlines
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
What is the core focus of Arcutis Biotherapeutics?
How does the company differentiate its product offerings?
What types of products does Arcutis offer?
What role do clinical trials play in their business model?
How is Arcutis positioned within the competitive dermatology market?
What is the significance of their non-steroidal formulations?
Can you elaborate on the company’s research and development efforts?
Is Arcutis involved in treatments for pediatric patients?
